OTC:ISCO
International Stem Cell CORP
A biotech firm advancing stem cell therapies with significant R&D investments but currently operating at a net loss.
Key Metrics
Investment Thesis
Bull Case
Investors might consider ISCO due to its high paid-in capital of $106.7M which suggests strong backing or prior equity success, and the potential for significant value creation if any stem cell products reach market approval. The recent revenue growth to $9.1M indicates an expanding business model that could accelerate once key milestones are achieved in their pipeline.
Bear Case
The company faces severe liquidity concerns with current liabilities of $4.7M far outweighing current assets of $3.6M, creating a precarious balance sheet for an unprofitable entity. With retained earnings deficit exceeding -$110M and no recent net income, the stock carries high risk of dilution or bankruptcy without a successful commercial breakthrough.
About International Stem Cell CORP
International Stem Cell Corp (ISCO) is a biotechnology company focused on developing cell therapy solutions and related technologies to treat various diseases. The company operates primarily in the global stem cell and regenerative medicine markets, leveraging its research and development efforts to create novel therapeutic products. Key revenue streams include licensing agreements, collaborative research partnerships, and potential product commercialization.
Analysis
Management Discussion
While revenue increased to $9.1M in the most recent year compared to prior years, the company continues to report a net loss driven by substantial general and administrative costs of $3.5M and marketing expenses of $1.2M. Cash flow from operations remains weak at only $13k, necessitating continued financing activities as evidenced by negative cash flow from financing of -$200k.
Industry Overview
The stem cell industry is characterized by high R&D costs, lengthy regulatory approval processes, and significant capital requirements before product monetization begins. Companies in this sector often operate at a loss for years while building intellectual property portfolios and conducting clinical trials to validate therapeutic efficacy.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $8.2M | $7.8M | $9.1M |
| Cost of Revenue | $3.3M | $3.2M | $3.8M |
| Gross Profit | $4.9M | $4.6M | $5.3M |
| Operating Expenses | $5.1M | $5.3M | $5.4M |
| Operating Income | $-183.0K | $-663.0K | $-68.0K |
| R&D | $492.0K | $511.0K | $657.0K |
| G&A | $3.4M | $3.5M | $3.5M |
| Marketing | $1.2M | $1.2M | $1.2M |
| Stock-Based Comp | $399.0K | $464.0K | $466.0K |
| D&A | $218.0K | $194.0K | $206.0K |
| Amortization | $81.0K | $82.0K | $82.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $532.0K | $-141.0K |
| Interest Expense | $135.0K | $139.0K | — |
| Pre-Tax Income | $-183.0K | $-131.0K | $-209.0K |
| Income Tax | $148.0K | $0 | $0 |
| Continuing Ops | $-331.0K | $-131.0K | $-209.0K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-331.0K | $-131.0K | $-209.0K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-331.0K | $-131.0K | $-209.0K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $3.0M | $3.5M | $3.6M |
| Accounts Receivable | $747.0K | $574.0K | $1.1M |
| Inventory | $1.4M | $1.3M | $1.1M |
| Prepaid Expenses | $90.0K | $96.0K | $123.0K |
| Other Current Assets | $742.0K | $1.6M | $1.2M |
| Long-Term Assets | $2.2M | $1.9M | $1.6M |
| PP&E (Net) | $248.0K | $215.0K | $257.0K |
| Intangibles | $878.0K | $800.0K | $721.0K |
| Operating Leases | $727.0K | $557.0K | $352.0K |
| Other LT Assets | $319.0K | $297.0K | $283.0K |
| Total Assets | $5.1M | $5.4M | $5.2M |
| Current Liabilities | $4.6M | $4.8M | $4.7M |
| Accounts Payable | $322.0K | $364.0K | $186.0K |
| Current Leases | $230.0K | $276.0K | $330.0K |
| Other Current Liab | $3.6M | $3.7M | $3.6M |
| Long-Term Liabilities | $720.0K | $445.0K | $115.0K |
| LT Operating Leases | $720.0K | $445.0K | $115.0K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $5.4M | $5.3M | $4.8M |
| Shareholders' Equity | $-220.0K | $113.0K | $370.0K |
| Paid-In Capital | $105.8M | $106.3M | $106.7M |
| Retained Earnings | $-110.3M | $-110.5M | $-110.7M |
| Total L&E | $5.1M | $5.4M | $5.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-331.0K | $-131.0K | $-209.0K |
| Non-Cash Adjustments | $779.0K | $1.4M | $-39.0K |
| Working Capital Changes | $-116.0K | $-291.0K | $261.0K |
| Cash from Operations | $332.0K | $929.0K | $13.0K |
| Capital Expenditures | $1.0K | $80.0K | $166.0K |
| Cash from Investing | $-11.0K | $-83.0K | $-171.0K |
| Cash from Financing | $250.0K | $0 | $-200.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $571.0K | $846.0K | $-358.0K |
| Beginning Cash | $171.0K | $742.0K | $1.6M |
| Ending Cash | $742.0K | $1.6M | $1.2M |
Frequently Asked Questions
How does International Stem Cell CORP make money?
The company's financials suggest three primary segments: 1) Research and Development services generating revenue through grants or contracts (indicated by high R&D spend of $657k), 2) Licensing and collaboration revenues from external partners, and 3) Potential future product sales once clinical trials progress.
What are the main risks for ISCO?
1) Persistent net losses of approximately $209k in the latest year indicating a path to profitability is uncertain, 2) High dependency on external funding given current liabilities exceed assets by nearly $4M, 3) Regulatory hurdles and clinical trial failures inherent to biotech development, and 4) Limited cash reserves of $1.2M compared to high operating expenses.
What is ISCO's competitive advantage?
1) Specialized expertise in stem cell biology offering a niche in the regenerative medicine market, 2) Strategic partnerships that likely provide non-dilutive funding to offset high operating costs, and 3) A substantial paid-in capital base of $106.7M providing runway for long-term research initiatives.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.